Endometriosis is a chronic inflammatory gynecologic disorder in which endometrial-like tissue grows outside the uterine cavity. While classically associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility, growing evidence supports that it is not purely a local disease. Instead, it behaves as a systemic condition with metabolic, immunologic, and microbial components that may interact to perpetuate symptoms.
A central emerging theme is the relationship between endometriosis and cholesterol biology. Cholesterol is more than a membrane structural component; it is a substrate for steroidogenesis and a regulator of inflammatory signaling and lipid raft organization. Observational and mechanistic studies suggest that women with endometriosis may show altered lipid profiles and dysregulated pathways involved in cholesterol transport and metabolism. One plausible link involves the way bioactive lipid mediators modulate macrophage polarization and cytokine production. When lipid homeostasis is disturbed, immune cells can shift toward pro-inflammatory phenotypes, potentially amplifying inflammatory cascades that contribute to lesion survival, pain sensitization, and recurrent tissue remodeling.
Inflammation is a defining feature of endometriosis pathophysiology. Ectopic lesions recruit and activate innate immune cells, particularly macrophages and neutrophils, and provoke elevated levels of inflammatory cytokines and chemokines in peritoneal fluid and lesion microenvironments. This inflammatory milieu can drive angiogenesis, fibrosis, and neuroangiogenesis, which may explain why pain can become chronic and disproportionate to visible lesion burden. In addition, oxidative stress and impaired tissue repair mechanisms may coexist, further sustaining ongoing inflammation.
The microbiome hypothesis provides an additional systems-level explanation. The microbiome refers to the collective genomes of microorganisms and their metabolites that inhabit body sites such as the gut, vagina, and possibly reproductive tract. Microbial communities influence immune tone by shaping pattern recognition receptor signaling and by producing metabolites (e.g., short-chain fatty acids) that can either promote or resolve inflammation. In endometriosis, studies have reported altered microbial composition and function, including differences in diversity and the relative abundance of taxa associated with inflammatory phenotypes. These changes may affect intestinal permeability and systemic immune activation, enabling a gut–pelvis axis in which inflammatory signals originating in the microbiome influence pelvic immune responses.
How cholesterol, inflammation, and the microbiome may converge is an area of active investigation. Microbial metabolites can affect host lipid metabolism, and conversely, host bile acid pools shaped by cholesterol and hepatic synthesis can feed back on microbial ecology. Bile acids also have direct immunomodulatory roles: they can act on receptors that regulate inflammatory gene expression and maintain mucosal barrier integrity. If endometriosis is associated with cholesterol alterations, the downstream effects on bile acids could alter microbial communities, shifting them toward pro-inflammatory functions and increasing susceptibility to chronic inflammation.
Beyond association, the clinical relevance of these pathways includes implications for biomarkers and therapeutics. If lipid alterations and specific microbiome signatures reliably correlate with disease status, lesion burden, or pain severity, they could help stratify patients. For example, metabolomic profiles involving lipid mediators might complement imaging and symptom assessment. Microbiome-derived biomarkers might also aid in predicting treatment response, including response to hormonal therapies or anti-inflammatory approaches.
Therapeutically, the systems perspective encourages targeted, biologically grounded interventions. Standard management remains hormonal suppression (e.g., progestins, combined oral contraceptives, gonadotropin-releasing hormone agonists/antagonists) and pain control, with surgery for selected cases. However, adjunct strategies are being explored: dietary modulation to support metabolic health, anti-inflammatory approaches, and interventions aimed at the gut microbiome such as evidence-informed dietary fiber strategies and, in some settings, probiotics. These ideas require careful validation because microbiome manipulation is complex and may vary by baseline community composition.
Importantly, endometriosis risk and severity are influenced by genetics, immune function, hormonal environment, and exposures. The microbiome and lipid systems likely represent mediators and amplifiers rather than sole causes. The heterogeneity of endometriosis—differences in lesion location, immune signatures, and symptom phenotypes—may explain why not all patients show the same degree of metabolic or microbial alterations.
In summary, endometriosis should be understood as a multifactorial chronic inflammatory disorder with systemic dimensions. Associations with cholesterol metabolism suggest dysregulated lipid signaling that may influence immune activation and lesion persistence. Concurrent inflammation provides the mechanistic bridge to chronic pain and tissue remodeling. Altered microbiome patterns offer a plausible upstream and reinforcing factor via metabolite-mediated immune modulation and barrier effects. Together, these insights support a more integrated model of endometriosis that may enable improved biomarkers and future therapies aimed at metabolic–inflammatory and microbial targets.
Source: [New Scientist]
New Scientist: Endometriosis is usually thought of as a gynaecological condition, but a huge study shows it has links with cholesterol levels, inflammation and an altered microbiome. #breaking
— @newscientist May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
